Sapu Nano's Deciparticle Platform Demonstrates Versatile Hydrophobic Drug Formulation Capabilities

Oncotelic Therapeutics Inc. (OTCQB: OTLC) announced that its 45%-owned joint venture, Sapu Nano, presented new data at the 2025 San Antonio Breast Cancer Symposium demonstrating the versatility of its Deciparticle nanomedicine platform. The findings show the platform can consistently formulate structurally diverse hydrophobic therapeutics into sub-20 nanometer nanoparticles suitable for intravenous delivery.

The data specifically highlighted successful formulation of multiple drug classes including macrolide mTOR inhibitors, cyclic and linear peptides, ascomycin macrolactams and polyketides. This broad formulation capability addresses a significant challenge in drug development, as many promising therapeutic compounds exhibit poor solubility that limits their clinical application. The Deciparticle platform transforms these hydrophobic drugs into nanoparticles that can be administered intravenously, potentially unlocking new treatment possibilities.

According to the company, these findings confirm Deciparticle as a versatile, cGMP-ready delivery platform backed by ISO-5 manufacturing capabilities that support rapid translation to Phase 1 clinical trial supply. The ISO-5 classification indicates the manufacturing environment meets stringent cleanroom standards required for producing sterile pharmaceutical products, suggesting the platform is positioned for clinical application.

Dr. Vuong Trieu, CEO of Oncotelic Therapeutics, stated that the results position Deciparticle as a modular engine for multiple oncology, immunology and peptide drug candidates. He noted that Sapu003 represents the first candidate in what is expected to be a broader pipeline leveraging this technology. The modular nature of the platform suggests it could be applied to various drug candidates without requiring extensive reformulation for each new compound.

The implications of this announcement extend beyond the specific data presented. For the pharmaceutical industry, a reliable platform for formulating hydrophobic drugs could accelerate development timelines and reduce formulation-related failures in drug development. Many promising drug candidates fail to reach patients due to formulation challenges rather than lack of efficacy, making technologies like Deciparticle potentially valuable for improving success rates in drug development.

For patients, particularly those with cancer and immunological conditions, successful implementation of this technology could lead to more treatment options becoming available. Hydrophobic compounds that previously couldn't be effectively delivered to patients might now be formulated into viable therapies. The sub-20 nanometer particle size is particularly significant as smaller nanoparticles typically exhibit improved tissue penetration and distribution compared to larger particles.

The announcement also highlights the strategic importance of Oncotelic's joint venture structure. Through its 45% ownership in Sapu Nano, Oncotelic gains access to platform technology that complements its existing oncology and immunotherapy focus. Additional information about Oncotelic Therapeutics is available through the company's newsroom at https://nnw.fm/OTLC. The original press release containing the Sapu Nano data can be accessed at https://nnw.fm/b0Qps.

As nanomedicine continues to evolve as a field, platforms like Deciparticle that offer standardized approaches to drug formulation could become increasingly important. The ability to consistently produce nanoparticles of specific sizes with diverse drug payloads represents a technical advancement that may influence how pharmaceutical companies approach formulation challenges. While the data presented focuses on specific drug classes, the platform's versatility suggests potential applications across multiple therapeutic areas beyond those initially targeted.